Asarina Pharma AB (publ) (ASAP.ST)
SEK 0.03
(-31.03%)
SEK 0.03
(-31.03%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -12.82 Million SEK | 3.43% |
| 2022 | -13.28 Million SEK | 58.04% |
| 2021 | -31.65 Million SEK | 57.93% |
| 2020 | -75.25 Million SEK | -5.88% |
| 2019 | -71.07 Million SEK | -61.44% |
| 2018 | -44.02 Million SEK | -55.59% |
| 2017 | -28.29 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q4 | -1.67 Million SEK | 0.0% |
| 2023 FY | -12.82 Million SEK | 3.43% |
| 2023 Q1 | -4.74 Million SEK | -86.55% |
| 2023 Q2 | -4.74 Million SEK | 0.0% |
| 2023 Q3 | -1.67 Million SEK | 64.8% |
| 2022 Q3 | -2.54 Million SEK | 40.61% |
| 2022 Q1 | -4.1 Million SEK | -284.36% |
| 2022 FY | -13.28 Million SEK | 58.04% |
| 2022 Q4 | -2.54 Million SEK | 0.0% |
| 2022 Q2 | -4.28 Million SEK | -4.31% |
| 2021 Q2 | -16.13 Million SEK | -154.55% |
| 2021 Q3 | -8.12 Million SEK | 49.65% |
| 2021 Q4 | -1.06 Million SEK | 86.85% |
| 2021 FY | -31.65 Million SEK | 57.93% |
| 2021 Q1 | -6.33 Million SEK | 66.02% |
| 2020 Q2 | -20.67 Million SEK | -12.58% |
| 2020 FY | -75.25 Million SEK | -5.88% |
| 2020 Q4 | -18.64 Million SEK | -6.18% |
| 2020 Q3 | -17.56 Million SEK | 15.08% |
| 2020 Q1 | -18.36 Million SEK | -15.87% |
| 2019 Q2 | -25.82 Million SEK | -173.81% |
| 2019 Q1 | -9.43 Million SEK | 32.87% |
| 2019 FY | -71.07 Million SEK | -61.44% |
| 2019 Q4 | -15.85 Million SEK | 20.63% |
| 2019 Q3 | -19.97 Million SEK | 22.65% |
| 2018 Q1 | -5.09 Million SEK | -63.71% |
| 2018 FY | -44.02 Million SEK | -55.59% |
| 2018 Q4 | -14.04 Million SEK | 7.76% |
| 2018 Q3 | -15.22 Million SEK | -56.23% |
| 2018 Q2 | -9.74 Million SEK | -91.38% |
| 2017 Q4 | -3.11 Million SEK | 12.44% |
| 2017 FY | -28.29 Million SEK | 0.0% |
| 2017 Q1 | -10.81 Million SEK | 0.0% |
| 2017 Q3 | -3.55 Million SEK | 67.15% |
| 2017 Q2 | -10.81 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 97.248% |
| AcouSort AB (publ) | -17.08 Million SEK | 24.934% |
| Active Biotech AB (publ) | -45.8 Million SEK | 71.991% |
| Alzinova AB (publ) | -16.48 Million SEK | 22.16% |
| Amniotics AB (publ) | -30.87 Million SEK | 58.445% |
| BioArctic AB (publ) | 229.24 Million SEK | 105.596% |
| Camurus AB (publ) | 431.44 Million SEK | 102.973% |
| Cantargia AB (publ) | -280.02 Million SEK | 95.419% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 39.178% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | 21.771% |
| Genovis AB (publ.) | 61.5 Million SEK | 120.859% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 88.68% |
| Mendus AB (publ) | -101.61 Million SEK | 87.376% |
| Kancera AB (publ) | -64.88 Million SEK | 80.231% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 338.173% |
| LIDDS AB (publ) | -40.2 Million SEK | 68.094% |
| Lipum AB (publ) | -37.17 Million SEK | 65.496% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -5.772% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 205.415% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | 28.323% |
| NextCell Pharma AB | -41.95 Million SEK | 69.428% |
| OncoZenge AB (publ) | -15.9 Million SEK | 19.331% |
| Saniona AB (publ) | -95.81 Million SEK | 86.611% |
| Simris Alg AB (publ) | -37.3 Million SEK | 65.613% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 95.874% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 96.695% |
| Xintela AB (publ) | -54.08 Million SEK | 76.281% |
| Ziccum AB (publ) | -21.41 Million SEK | 40.09% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 65.396% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 92.86% |
| CombiGene AB (publ) | -35.66 Million SEK | 64.032% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 91.552% |
| Intervacc AB (publ) | -102.85 Million SEK | 87.528% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 94.84% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -2828.767% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | 22.363% |
| Corline Biomedical AB | -1.8 Million SEK | -609.121% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 92.787% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 77.424% |
| Aptahem AB (publ) | -11.11 Million SEK | -15.434% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 89.576% |
| Fluicell AB (publ) | -26.55 Million SEK | 51.691% |
| Biovica International AB (publ) | -124.82 Million SEK | 89.723% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 69.618% |
| Abliva AB (publ) | -95.5 Million SEK | 86.569% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 96.076% |
| 2cureX AB (publ) | -32.51 Million SEK | 60.551% |
| I-Tech AB | 20.2 Million SEK | 163.496% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 98.458% |
| Cyxone AB (publ) | -22.98 Million SEK | 44.199% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 85.965% |
| Biosergen AB | -27.03 Million SEK | 52.554% |
| Nanologica AB (publ) | -75.15 Million SEK | 82.932% |
| SynAct Pharma AB | -215.81 Million SEK | 94.056% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 70.881% |
| BioInvent International AB (publ) | -330.3 Million SEK | 96.116% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 45.958% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 94.85% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -29.184% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 88.262% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -9.848% |